Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges

Author(s): Chiranjib Chakraborty, Zhi-Hong Wen, Govindasamy Agoramoorthy, Chan-Shing Lin

Journal Name: Current Drug Metabolism

Volume 17 , Issue 5 , 2016

Become EABM
Become Reviewer


Background: Over the decade, miRNAs are the most important molecules for the biopharmaceutical industry due to their relation with several human diseases. Presently, the phase-II clinical trial has been initiated for the first miRNA-based therapeutics (“Miravirsen”) to treat HCV infection. It has been expected that many more miRNA-based therapeutics will enter the clinical trials. Therefore, it is important to develop different kinds of novel delivery systems with better efficacy and more efficiency, but fewer side effects.

Methods: We have undertaken a structured search of bibliographic databases for peer-reviewed research literature to solve our review question. Literature survey was performed widely to write this review article.

Results: In this review, we have discussed the various types of miRNA delivery systems such as viral vectors, lipid-based systems, nanocarriers, and LNA-customized DNA delivery without any delivery-mediated agent. Current status, technical support, and the future challenges for miRNA-based delivery are also discussed.

Conclusion: Recent development and understanding of miRNA had shown the therapeutic potentiality of miRNA.

Keywords: Biopharmaceutical industry, cancer therapy, miRNA delivery, therapeutic microRNA, tumorigenesis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 24 March, 2016
Page: [469 - 477]
Pages: 9
DOI: 10.2174/1389200217666160126142408
Price: $65

Article Metrics

PDF: 52
PRC: 1